Document is current
Any future updates will be listed below
-
Authors
Garofano, Luciano https://orcid.org/0000-0001-8582-0865
Migliozzi, Simona
Oh, Young Taek
D’Angelo, Fulvio https://orcid.org/0000-0002-4940-4693
Najac, Ryan D.
Ko, Aram
Frangaj, Brulinda
Caruso, Francesca Pia https://orcid.org/0000-0002-2206-1459
Yu, Kai
Yuan, Jinzhou
Zhao, Wenting
Di Stefano, Anna Luisa
Bielle, Franck
Jiang, Tao https://orcid.org/0000-0002-7008-6351
Sims, Peter
Suvà, Mario L.
Tang, Fuchou https://orcid.org/0000-0002-8625-7717
Su, Xiao-Dong
Ceccarelli, Michele https://orcid.org/0000-0002-4702-6617
Sanson, Marc
Lasorella, Anna https://orcid.org/0000-0002-1839-5421
Iavarone, Antonio https://orcid.org/0000-0002-0683-4634
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (R01CA101644, U54CA193313, R01CA131126, R01CA178546, U54CA193313, R01CA179044, R01CA190891, R01CA239698)
Associazione Italiana per la Ricerca sul Cancro (IG 2018 ID. 21846)
The Chemotherapy Foundation grant to A.I.
- License Information
-
More Information
Article History
Received: 10 June 2020
Accepted: 25 November 2020
First Online: 11 January 2021
Competing interests
: A.L. and A.I. are inventors of a biomarker technology that has been licensed to QIAGEN. A.I. received sponsored research funding from AstraZeneca and Taiho Pharmaceutical and has served as a paid consultant/advisor to AIMEDBIO Inc. A.L. received sponsored research funding from Celgene. All other authors declare no competing interests.
